ライフサイエンスコーパス: rabies vaccine

1 fluenced the prevalence of antibodies to the rabies vaccine.

2 99 to receive RTS,S/AS01 and 101 to receive rabies vaccine.

3 ping potential therapeutics and an avirulent rabies vaccine.

4 guide the development of a single-dose human rabies vaccine.

5 s, were randomized to receive RTS,S/AS01E or rabies vaccine.

6 r (GM-CSF) can enhance the immunogenicity of rabies vaccines.

7 hich will help in designing more efficacious rabies vaccines.

8 implications in the development of efficient rabies vaccines.

9 crease our ability to produce more-effective rabies vaccines.

10 need to develop single-dose and long-lasting rabies vaccines.

11 which may help in designing more-efficacious rabies vaccines.

12 ses of RTS,S/AS01E vaccine (223 children) or rabies vaccine (224 controls).

13 mug Matrix-M or a control vaccine (licensed rabies vaccine [Abhayrab]).

14 ecombinant glycoprotein (rgp) 120 or subunit rabies vaccine administered by the intramuscular route.

15 d in the form of an effective oral wild-life rabies vaccine, although no product for humans has been

16 al immune responses to two priming antigens, rabies vaccine and an adenovirus-based severe acute resp

17 el highlights the safety of third generation rabies vaccines and serves as a platform for standardize

18 omising candidate vector for a transmissible rabies vaccine, and provide a framework to discover and

19 ly a total of 81 (57.0%) tested positive for rabies vaccine antibodies, possibly, due to the delayed

20 Rabies vaccines are a critical component in the strategy

21 While rabies vaccines are inactivated and thus have an excelle

22 Nevertheless, an experimental rabies vaccine based on the Pittman Moore vaccine strain

23 ovide a basis from which to develop improved rabies vaccines based on RABV-G stabilized in the prefus

24 receive three doses of either RTS,S/AS01 or rabies vaccine (both 0.5 mL per dose by intramuscular in

25 This is first report of an orally effective rabies vaccine candidate in animals based on PIV5 as a v

26 ChAdOx2 RabG, a simian adenovirus-vectored rabies vaccine candidate, might have potential to provid

27 n naive volunteers during a 3-dose course of rabies vaccine compared with the B-cell response to a bo

28 oculating a single bat with a DrBHV-vectored rabies vaccine could immunize >80% of a bat population,

29 andidate for a new generation of recombinant rabies vaccine for humans and animals and PIV5 is a pote

30 ecommends intradermal (ID) administration of rabies vaccine for preexposure prophylaxis.

31 Currently, safe and efficacious rabies vaccines for humans and animals are produced in s

32 orld Health Organization (WHO) pre-qualified rabies vaccines for humans are inactivated tissue cultur

33 ith the B-cell response to a booster dose of rabies vaccine given to previously immunized volunteers.

34 Rabies vaccines have evolved from the first crude nerve

35 0.1 mL ID of the human diploid cell culture rabies vaccine [HDCV] at days 0 and 7) vs a standard 3-v

36 rimary and secondary immune responses to the rabies vaccine in humans.

37 who received human rabies immune globulin or rabies vaccine in the ED from January 2015 to June 2018

38 Semple rabies vaccine-induced autoimmune encephalomyelitis (SAE

39 Semple rabies vaccine is derived from brain tissue infected wit

40 prophylaxis using rabies immune globulin and rabies vaccine is effective in preventing rabies followi

41 An efficacious and cost-effective rabies vaccine is needed.

42 ministration of the first dose of a licensed rabies vaccine, nine participants had virus neutralising

43 A next-generation Vero cell rabies vaccine (PVRV-NG2) was developed using the same P

44 recipients and 37 (36.6%, 27.3-46.8) of 101 rabies-vaccine recipients (relative risk 1.1, 95% CI 0.8

45 1 recipients and four (4.0%, 1.1-9.8) of 101 rabies-vaccine recipients died, but no deaths were deeme

46 1 recipients and 12 (11.9%, 6.3-19.8) of 101 rabies-vaccine recipients had at least one serious adver

47 case of Haemophilus influenza meningitis (1% rabies-vaccine recipients), and one case of tuberculosis

48 of pneumonia (1% RTS,S/AS01 recipients vs 3% rabies-vaccine recipients), five cases of gastroenteriti

49 troenteritis (3% RTS,S/AS01 recipients vs 2% rabies-vaccine recipients), five cases of malnutrition (

50 -vaccine recipients), one case of sepsis (1% rabies-vaccine recipients), one case of Haemophilus infl

51 malnutrition (2% RTS,S/AS01 recipients vs 3% rabies-vaccine recipients), one case of sepsis (1% rabie

52 he gut microbiome in individuals receiving a rabies vaccine, resulting in systemic inflammatory respo

53 71%]; P = .009), administration distant from rabies vaccine site (180 of 254 [71%] to 58 of 70 [83%];

54 ion into wounds, administration distant from rabies vaccine site, and administration that avoids the

55 ate among mice inoculated with an attenuated rabies vaccine strain, recombinant LBNSE.

56 Existing rabies vaccines target the rabies virus glycoprotein (RA

57 In this study, a novel rabies vaccine that expressed murine IL-7 was developed.

58 (1:1:1:1:1) to one of five groups to receive rabies vaccine (the control group) at months 0, 1, and 2

59 ss efficient and unsafe nerve-tissue-derived rabies vaccines, the burden of this disease could be sub

60 ody maintenance then administered a licensed rabies vaccine (to simulate post-exposure prophylaxis) a

61 (PEP) currently comprises administration of rabies vaccine together with rabies immunoglobulin (RIG)

62 us can be targeted to increase the safety of rabies vaccine vectors.

63 emulsion (GLA-SE; 2.5 or 5 mug), or control rabies vaccine (Verorab) were administered intramuscular

64 e to the delayed uptake of bait in which the rabies vaccine was already inactivated.

65 coma while a native immune response matured; rabies vaccine was not administered.

66 Response to the rabies vaccine was not significantly associated with bir

67 ration of sequential doses of an intradermal rabies vaccine was shown to result in reduced vaccine im

68 In this work, a PIV5-vectored rabies vaccine was tested in mice.

69 VE (RTS,S/AS01E vs rabies vaccine) was 34.8% (95% confidence interval [CI],

70 vaccine for Salmonella typhi and 2 doses of rabies vaccine were given to each subject.

71 Cases with at least one documented dose of rabies vaccine were included.

72 from healthy adults immunised with licensed rabies vaccine, were generated.

73 rategy to develop a single-dose postexposure rabies vaccine where the generation of early protective

74 ld be strongly advised to be vaccinated with rabies vaccines, which are effective against EBLV-1.